What are the typical manifestations of dermatomyositis and what are the diagnostic criteria?

Manifestations and Diagnostic Criteria for Dermatomyositis

Dermatomyositis presents with characteristic cutaneous findings including Gottron papules, heliotrope rash, and periorbital edema, combined with symmetric proximal muscle weakness developing over weeks to months, and is diagnosed using the Bohan and Peter criteria requiring 4 of 5 features: characteristic skin findings, proximal muscle weakness, elevated muscle enzymes, myopathic EMG pattern, and inflammatory infiltrate on muscle biopsy 1.

Classic Cutaneous Manifestations

The skin findings are often the most recognizable features and include 1:

• Gottron papules: Erythematous papules over the extensor surfaces of joints (metacarpophalangeal, proximal interphalangeal, elbows, knees)
• Heliotrope rash: Violaceous periorbital edema with erythema
• Poikiloderma: Photosensitive erythematous rash with telangiectasias
• Periungual telangiectasias: Dilated capillaries at the nail folds
• Distribution: Face, neck, torso, fingers, and extensor surfaces of extremities

Important caveat: Cutaneous vasculitis, ulcerations, and calcinosis are uncommon in adult dermatomyositis but are characteristic features of juvenile dermatomyositis 1.

Muscle Involvement

Symmetric proximal muscle weakness develops over weeks to months with the following features 1:

• Pattern: Difficulty rising from chairs, climbing stairs, lifting arms overhead
• Laboratory: Elevated creatine kinase and other muscle enzymes
• EMG findings: Polyphasic motor unit action potentials of short duration and low amplitude, increased insertional activity with fibrillation potentials, sharp waves, and repetitive discharges
• Dysphagia: Due to cricopharyngeal weakness or spasm, evident on videofluoroscopy 1

Systemic Manifestations

Multiple organ systems may be involved 1:

• Pulmonary: Interstitial lung disease (most common pattern is nonspecific interstitial pneumonitis) or aspiration pneumonia from ventilatory muscle weakness
• Cardiac: Often asymptomatic—sinus tachycardia on ECG, diastolic dysfunction on echocardiography; myocarditis found on autopsy studies though severe cardiac manifestations are atypical
• Gastrointestinal: Dysphagia is the primary manifestation

Diagnostic Criteria (Bohan and Peter)

The established diagnostic criteria require 4 of the following 5 features 1:

1. Characteristic skin findings (Gottron papules, heliotrope rash, periorbital edema)
2. Proximal muscle weakness
3. Elevated muscle enzyme levels
4. Myopathic pattern on electromyography
5. Evidence of endomysial, mononuclear inflammatory infiltrate on muscle biopsy

Modern Classification: EULAR/ACR Criteria (2017)

The more recent EULAR/ACR classification criteria use a probability-based scoring system 2:

• Definite IIM: Probability ≥90% (score ≥7.5 without biopsy, ≥8.7 with biopsy)
• Probable IIM: Probability ≥55% and <90% (score ≥5.5 without biopsy, ≥6.7 with biopsy)
• Possible IIM: Probability ≥50% and <55%

Critical distinction: For patients with pathognomonic skin rashes of dermatomyositis, classification criteria were developed that do not require muscle biopsy data. However, where no skin rash is present, a muscle biopsy is required 2.

Important Clinical Subtypes

Amyopathic Dermatomyositis

Patients have classic dermatomyositis rash without muscle weakness, normal muscle enzyme levels within 2 years of diagnosis, and normal EMG findings 1. Pitfall: These patients can still develop interstitial lung disease and have malignancy risk, though lower than classic dermatomyositis 1.

Hypomyopathic Dermatomyositis

Patients lack muscle weakness but show evidence of muscle inflammation: mild CK elevation, EMG abnormalities, MRI evidence of muscle inflammation, or abnormal muscle biopsy 1.

Juvenile Dermatomyositis

Affects children <18 years with distinctive features 1:

• Proximal muscle weakness
• Calcinosis cutis (more common than in adults)
• Cutaneous vasculitis and ulcerations
• Gastrointestinal vasculopathy
• Nailfold capillaroscopy is particularly useful for predicting disease severity

Myositis-Specific Autoantibodies

Emerging evidence shows that autoantibody profiles define distinct phenotypes with prognostic implications 1, 3:

• Anti-Mi2: Classic dermatomyositis phenotype
• Anti-TIF1γ: High malignancy risk
• Anti-MDA5: High risk for rapidly progressive interstitial lung disease
• Anti-NXP2: Malignancy association
• Anti-SAE: Distinct clinical features

These antibodies help predict extramuscular organ involvement (pulmonary, cardiac) and offer long-term prognostic information 1.

Diagnostic Imaging

MRI with T1-weighted, T2-weighted, and fat suppression techniques (STIR sequences) provides useful information to 1:

• Identify optimal muscle biopsy site
• Diagnose myositis
• Monitor treatment response

Common Diagnostic Pitfalls

1. Amyopathic forms may be missed if clinicians rely solely on muscle symptoms—the skin findings alone warrant full evaluation 4
2. Cardiac involvement is often asymptomatic—screening ECG and echocardiography are necessary 1
3. Approximately 25% of amyopathic dermatomyositis patients lack 2 of 3 classic skin features and may be misdiagnosed as lupus erythematosus 4
4. Malignancy screening is mandatory in adults, as cancer risk is highest within 3 years before or after dermatomyositis diagnosis 5